ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

Jianfeng Shen, Zhenlin Ju, Wei Zhao, Lulu Wang, Yang Peng, Zhongqi Ge, Zachary D. Nagel, Jun Zou, Chen Wang, Prabodh Kapoor, Xiangyi Ma, Ding Ma, Jiyong Liang, Shumei Song, Jinsong Liu, Leona D. Samson, Jaffer A. Ajani, Guo Min Li, Han Liang, Xuetong ShenGordon Mills, Guang Peng

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer 1,2 . The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression 3, which makes ARID1A a poor therapeutic target. Therefore, it is of clinical importance to identify molecular consequences of ARID1A deficiency that create therapeutic vulnerabilities in ARID1A-mutant tumors. In a proteomic screen, we found that ARID1A interacts with mismatch repair (MMR) protein MSH2. ARID1A recruited MSH2 to chromatin during DNA replication and promoted MMR. Conversely, ARID1A inactivation compromised MMR and increased mutagenesis. ARID1A deficiency correlated with microsatellite instability genomic signature and a predominant C>T mutation pattern and increased mutation load across multiple human cancer types. Tumors formed by an ARID1A-deficient ovarian cancer cell line in syngeneic mice displayed increased mutation load, elevated numbers of tumor-infiltrating lymphocytes, and PD-L1 expression. Notably, treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors. Together, these results suggest ARID1A deficiency contributes to impaired MMR and mutator phenotype in cancer, and may cooperate with immune checkpoint blockade therapy.

Original languageEnglish (US)
Pages (from-to)556-562
Number of pages7
JournalNature Medicine
Volume24
Issue number5
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

DNA Mismatch Repair
Tumors
Immunity
Repair
Mutation
Neoplasms
Bearings (structural)
Tumor-Infiltrating Lymphocytes
Therapeutics
Microsatellite Instability
Mutagenesis
Lymphocytes
Neoplasm Genes
Tumor Burden
DNA Replication
Microsatellite Repeats
Proteomics
Ovarian Neoplasms
Chromatin
Genes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. / Shen, Jianfeng; Ju, Zhenlin; Zhao, Wei; Wang, Lulu; Peng, Yang; Ge, Zhongqi; Nagel, Zachary D.; Zou, Jun; Wang, Chen; Kapoor, Prabodh; Ma, Xiangyi; Ma, Ding; Liang, Jiyong; Song, Shumei; Liu, Jinsong; Samson, Leona D.; Ajani, Jaffer A.; Li, Guo Min; Liang, Han; Shen, Xuetong; Mills, Gordon; Peng, Guang.

In: Nature Medicine, Vol. 24, No. 5, 01.05.2018, p. 556-562.

Research output: Contribution to journalArticle

Shen, J, Ju, Z, Zhao, W, Wang, L, Peng, Y, Ge, Z, Nagel, ZD, Zou, J, Wang, C, Kapoor, P, Ma, X, Ma, D, Liang, J, Song, S, Liu, J, Samson, LD, Ajani, JA, Li, GM, Liang, H, Shen, X, Mills, G & Peng, G 2018, 'ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade', Nature Medicine, vol. 24, no. 5, pp. 556-562. https://doi.org/10.1038/s41591-018-0012-z
Shen, Jianfeng ; Ju, Zhenlin ; Zhao, Wei ; Wang, Lulu ; Peng, Yang ; Ge, Zhongqi ; Nagel, Zachary D. ; Zou, Jun ; Wang, Chen ; Kapoor, Prabodh ; Ma, Xiangyi ; Ma, Ding ; Liang, Jiyong ; Song, Shumei ; Liu, Jinsong ; Samson, Leona D. ; Ajani, Jaffer A. ; Li, Guo Min ; Liang, Han ; Shen, Xuetong ; Mills, Gordon ; Peng, Guang. / ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. In: Nature Medicine. 2018 ; Vol. 24, No. 5. pp. 556-562.
@article{045b3a95162f43f097c602798fb6f54a,
title = "ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade",
abstract = "ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer 1,2 . The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression 3, which makes ARID1A a poor therapeutic target. Therefore, it is of clinical importance to identify molecular consequences of ARID1A deficiency that create therapeutic vulnerabilities in ARID1A-mutant tumors. In a proteomic screen, we found that ARID1A interacts with mismatch repair (MMR) protein MSH2. ARID1A recruited MSH2 to chromatin during DNA replication and promoted MMR. Conversely, ARID1A inactivation compromised MMR and increased mutagenesis. ARID1A deficiency correlated with microsatellite instability genomic signature and a predominant C>T mutation pattern and increased mutation load across multiple human cancer types. Tumors formed by an ARID1A-deficient ovarian cancer cell line in syngeneic mice displayed increased mutation load, elevated numbers of tumor-infiltrating lymphocytes, and PD-L1 expression. Notably, treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors. Together, these results suggest ARID1A deficiency contributes to impaired MMR and mutator phenotype in cancer, and may cooperate with immune checkpoint blockade therapy.",
author = "Jianfeng Shen and Zhenlin Ju and Wei Zhao and Lulu Wang and Yang Peng and Zhongqi Ge and Nagel, {Zachary D.} and Jun Zou and Chen Wang and Prabodh Kapoor and Xiangyi Ma and Ding Ma and Jiyong Liang and Shumei Song and Jinsong Liu and Samson, {Leona D.} and Ajani, {Jaffer A.} and Li, {Guo Min} and Han Liang and Xuetong Shen and Gordon Mills and Guang Peng",
year = "2018",
month = "5",
day = "1",
doi = "10.1038/s41591-018-0012-z",
language = "English (US)",
volume = "24",
pages = "556--562",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

AU - Shen, Jianfeng

AU - Ju, Zhenlin

AU - Zhao, Wei

AU - Wang, Lulu

AU - Peng, Yang

AU - Ge, Zhongqi

AU - Nagel, Zachary D.

AU - Zou, Jun

AU - Wang, Chen

AU - Kapoor, Prabodh

AU - Ma, Xiangyi

AU - Ma, Ding

AU - Liang, Jiyong

AU - Song, Shumei

AU - Liu, Jinsong

AU - Samson, Leona D.

AU - Ajani, Jaffer A.

AU - Li, Guo Min

AU - Liang, Han

AU - Shen, Xuetong

AU - Mills, Gordon

AU - Peng, Guang

PY - 2018/5/1

Y1 - 2018/5/1

N2 - ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer 1,2 . The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression 3, which makes ARID1A a poor therapeutic target. Therefore, it is of clinical importance to identify molecular consequences of ARID1A deficiency that create therapeutic vulnerabilities in ARID1A-mutant tumors. In a proteomic screen, we found that ARID1A interacts with mismatch repair (MMR) protein MSH2. ARID1A recruited MSH2 to chromatin during DNA replication and promoted MMR. Conversely, ARID1A inactivation compromised MMR and increased mutagenesis. ARID1A deficiency correlated with microsatellite instability genomic signature and a predominant C>T mutation pattern and increased mutation load across multiple human cancer types. Tumors formed by an ARID1A-deficient ovarian cancer cell line in syngeneic mice displayed increased mutation load, elevated numbers of tumor-infiltrating lymphocytes, and PD-L1 expression. Notably, treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors. Together, these results suggest ARID1A deficiency contributes to impaired MMR and mutator phenotype in cancer, and may cooperate with immune checkpoint blockade therapy.

AB - ARID1A (the AT-rich interaction domain 1A, also known as BAF250a) is one of the most commonly mutated genes in cancer 1,2 . The majority of ARID1A mutations are inactivating mutations and lead to loss of ARID1A expression 3, which makes ARID1A a poor therapeutic target. Therefore, it is of clinical importance to identify molecular consequences of ARID1A deficiency that create therapeutic vulnerabilities in ARID1A-mutant tumors. In a proteomic screen, we found that ARID1A interacts with mismatch repair (MMR) protein MSH2. ARID1A recruited MSH2 to chromatin during DNA replication and promoted MMR. Conversely, ARID1A inactivation compromised MMR and increased mutagenesis. ARID1A deficiency correlated with microsatellite instability genomic signature and a predominant C>T mutation pattern and increased mutation load across multiple human cancer types. Tumors formed by an ARID1A-deficient ovarian cancer cell line in syngeneic mice displayed increased mutation load, elevated numbers of tumor-infiltrating lymphocytes, and PD-L1 expression. Notably, treatment with anti-PD-L1 antibody reduced tumor burden and prolonged survival of mice bearing ARID1A-deficient but not ARID1A-wild-type ovarian tumors. Together, these results suggest ARID1A deficiency contributes to impaired MMR and mutator phenotype in cancer, and may cooperate with immune checkpoint blockade therapy.

UR - http://www.scopus.com/inward/record.url?scp=85046552398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046552398&partnerID=8YFLogxK

U2 - 10.1038/s41591-018-0012-z

DO - 10.1038/s41591-018-0012-z

M3 - Article

C2 - 29736026

AN - SCOPUS:85046552398

VL - 24

SP - 556

EP - 562

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 5

ER -